plecanatide Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
peptides and glycopeptides 5208 467426-54-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • plecanatide
  • trulance
  • SP-304
Plecanatide is structurally related to human uroguanylin, and similar to uroguanylin, plecanatide functions as a guanylate cyclase-C (GC-C) agonist. Both plecanatide and its active metabolite bind to GC-C and act locally on the luminal surface of the intestinal epithelium. Activation of GC-C results in an increase in both intracellular and extracellular concentrations of cyclic guanosine monophosphate (cGMP). Elevation of intracellular cGMP stimulates secretion of chloride and bicarbonate into the intestinal lumen, mainly through activation of the cystic fibrosis transmembrane conductance regulator (CFTR) ion channel, resulting in increased intestinal fluid and accelerated transit.
  • Molecular weight: 1681.89
  • Formula: C65H104N18O26S4
  • CLOGP:
  • LIPINSKI: None
  • HAC: 44
  • HDO: 23
  • TPSA: 718.13
  • ALOGS:
  • ROTB: 28

Drug dosage:

DoseUnitRoute
3 mg O

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Jan. 19, 2017 FDA SYNERGY PHARMS INC

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

Pharmacologic Action:

SourceCodeDescription
ATC A06AX07 ALIMENTARY TRACT AND METABOLISM
DRUGS FOR CONSTIPATION
DRUGS FOR CONSTIPATION
Other drugs for constipation
FDA EPC N0000185500 Guanylate Cyclase-C Agonist
FDA MoA N0000185499 Guanylate Cyclase Activators
MeSH PA D020536 Enzyme Activators
MeSH PA D005765 Gastrointestinal Agents
MeSH PA D000074268 Guanylyl Cyclase C Agonists

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Chronic idiopathic constipation indication 82934008

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.25 acidic
pKa2 3.45 acidic
pKa3 3.97 acidic
pKa4 4.37 acidic
pKa5 11.74 acidic
pKa6 12.37 acidic
pKa7 12.62 acidic
pKa8 12.7 acidic
pKa9 13.22 acidic
pKa10 13.36 acidic
pKa11 13.36 acidic
pKa12 13.57 acidic
pKa13 13.71 acidic
pKa14 13.79 acidic
pKa15 7.52 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
3MG TRULANCE SALIX N208745 Jan. 19, 2017 RX TABLET ORAL 8637451 March 28, 2022 ELEVATION OF INTRACELLULAR CGMP RESULTING IN INCREASED INTESTINAL FLUID AND ACCELERATED TRANSIT
3MG TRULANCE SALIX N208745 Jan. 19, 2017 RX TABLET ORAL 9610321 Sept. 15, 2031 CHRONIC IDIOPATHIC CONSTIPATION
3MG TRULANCE SALIX N208745 Jan. 19, 2017 RX TABLET ORAL 9610321 Sept. 15, 2031 IRRITABLE BOWEL SYNDROME WITH CONSTIPATION
3MG TRULANCE SALIX N208745 Jan. 19, 2017 RX TABLET ORAL 9919024 Sept. 15, 2031 CHRONIC IDIOPATHIC CONSTIPATION
3MG TRULANCE SALIX N208745 Jan. 19, 2017 RX TABLET ORAL 9919024 Sept. 15, 2031 IRRITABLE BOWEL SYNDROME WITH CONSTIPATION

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
3MG TRULANCE SALIX N208745 Jan. 19, 2017 RX TABLET ORAL Jan. 24, 2021 TREATMENT IN ADULT PATIENTS FOR IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C)
3MG TRULANCE SALIX N208745 Jan. 19, 2017 RX TABLET ORAL Jan. 19, 2022 NEW CHEMICAL ENTITY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Heat-stable enterotoxin receptor Enzyme AGONIST EC50 6.72 SCIENTIFIC LITERATURE DRUG LABEL
Tumor necrosis factor Cytokine Kd 8.42 CHEMBL

External reference:

IDSource
7IK8Z952OK UNII
9367 INN_ID
CHEMBL255489 ChEMBL_ID
D09948 KEGG_DRUG
DB13170 DRUGBANK_ID
CHEMBL2103867 ChEMBL_ID
CHEMBL2105240 ChEMBL_ID
70693500 PUBCHEM_CID
9069 IUPHAR_LIGAND_ID
C584575 MESH_SUPPLEMENTAL_RECORD_UI
763544006 SNOMEDCT_US
017076 NDDF
32292 MMSL
d08521 MMSL
1873752 RXNORM
4036439 VANDF
725134000 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Trulance HUMAN PRESCRIPTION DRUG LABEL 1 65649-003 TABLET 3 mg ORAL NDA 17 sections
Trulance HUMAN PRESCRIPTION DRUG LABEL 1 70194-003 TABLET 3 mg ORAL NDA 18 sections